CA1294218C

CA1294218C - Method and agents for inhibiting protein aging

Info

Publication number: CA1294218C
Application number: CA000521807A
Authority: CA
Inventors: Anthony Cerami; Peter Ulrich; Michael Brownlee
Original assignee: Rockefeller University
Current assignee: Rockefeller University
Priority date: 1984-03-19
Filing date: 1986-10-30
Publication date: 1992-01-14
Anticipated expiration: 2009-01-14

Abstract

ABSTRACT OF THE DISCLOSURE

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group, and may further be at least partially derived from amino acids. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and lysine.
The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Description

2~8 This invention was made with partlal assistance from grants from the National Institutes of Health and the Bxookdale Foundation.

RELATED PUBLICATIONS

The Applicants are co~authors of the following articles directed to the subject matter o~ the present invention:
"COVALENT ATTACHMENT OF SOLUBLE PROTEINS BY NONENZYMATICALLY
GLYCOSYLATED COLLAGEN~ ROLE IN THE IN SITU FORMATION OF
IMMUNE COMPLEXES", Brownlee M., Pongor S., Cerami A., (1983), J. EXP. MED., Vol. 158, pp. 1739-1744 and "AGING OF
PROTEINS: ISOLATION AND IDENTIFICATION OF A FLUORESCENT
CHROMOPHORE FROM THE REACTION OF POLYPEPTIDES WITH GLUCOSE", Pongor, S., Ulrich, P., Bencsath, A.A., and Cerami, A.~
PROC. NATL. ACAD. SCI. USA, Vol. 81, pp. 2684-2688, (May, 1984).

BACRGROUND OF THE INVENTION

The present invention relates generally to the aglng of proteins resulting from reaction of glucose, and particu-larly to the nonenzymatic glycosylation of proteins and subsequent reactions leading to advanced glycosylation end products, and to methods and agents for their inhibition.

The reaction between glucose and proteins has been known for some time. Its earliest manifestation was in the `~

appearance of brown pigments during the cooking of food, which was identified by Maillard in 1912, who observed that glucose or other reducing sugars react with amino acids to form adducts that undergo a series of dehydrations and rearrangements to form stable brown pigments. Ma;llard, L.C. (1912) C.R. Acad. Sci., Vol.
- 154, pp. 66-68.

In the years that followed the initial discovery by Maillard, food chemists studied the hypothesized reaction in detail and determined that stored and heat treated foods undergo nonenzymatic browning as a result of the reaction between glucose and the polypeptide chain, and that the proteins are resultingly crosslinked and correspondingly exhibit decreased bioavailability.
Finot, P.A. (1~82) in Modification of Proteins, eds, Feeney, R.E. and Whitaker, J.R., American Chemical Society, Vol. 198, pp. 91-124, Washington, D.C. At this point, it was determined that the pigments responsible for the development of the brown color that develops as a result of protein glycosylation possessed characteristic spectra and fluorescent properties, however the chemical structure of the pigments had not been specifically elucidated.

The reaction between reducing sugars and food proteins discussed above was found in recent years to have its parallel in vivo. Thus, the nonenzymatic reaction between glucose and the free amino groups on proteins to form a stable amino, 1-deoxy ketosyl adduct, known as the Amadori product, has been shown to occur with hemoglobin, wherein a rearrangement o~ the amino terminal o-f the ~-chain of hemoglobin by reaction with glucose, forms the adduct known as hemoglobin A1C. The reaction has also been found to occur with a variety of other body proteins, such as lens crystallins, collagen and nerve proteins. See, Bunn, H.F.~ Haney, D.N., Gabbay, K.H. and 6allop, P.H., (1975) Biochem. Biophys. Res. Comm. Vol.

67, pp. 103-109; Koenig, R.J., Blobstein, S.H. and Cerami, A., (1977) J. Biol. Chem. Vol. 252, pp. 2992-2997;
Monnier, V.M. and Cerami, A., (1983) in Maillard Reaction in Food and Nutrition, ed. Waller, G.A., American Chemical Society, Vol. 215, pp. 431-448; and Monnier, V.M. and Cerami, A., (1982) Clinics in Endocrinology and Metabolism Vol. 11, pp. 431-452. Moreover, brown pigments with spectral and fluorescent properties similar to those of late-stage Maillard products have also been observed in vivo in association with several long-lived proteins, such as lens proteins and collagen from aged individuals. An age related linear increase in pigment was observed in human dura collagen between the ages of 20 to 90 years. See, Monnier, V.M and Ceraml, A. (1981) Science, Vol. 211, pp.
491-493; Monnier, V.M. and Cerami, A., (1983) Blochem.
Bioph~rs. Acta, Vol. 760, pp. 97-103; and, Monnier, V.M., Kohn, R.R. and Cerami, A., "Accelerated Age-Related Browning of Human Collagen in Diabetes Mellitus", (1984) Proc. Nat.
Acad. Sci. Vol. 81;, pp. 583-587. Injterestingly, the aging of collagen can be mimicked in vitro by the crosslinking induced by glucose; and the capture of other proteins and the formation of adducts by collagen, also noted, is theorized to occur by a cro~slinking reaction, and is believed to account for the observed accumulation of albumin and antibodies in kidney basement membrane. See, Brownlee, M., Pongor, S., and Cerami, A., (1983) J. Exp. Med., Vol.
158, pp. 1739-1744; and Kohn, R.R.,Cerami, A. and Monnier, V.M., (1984) Diabetes, Vol. 33, No. 1, pp. 57-59.

In Canadian Patent 1,250,587 , issued February 28, 1989, A. Cerami and in Pongor, S~Mo r et al., Supra., fluores-cent chromophore was isolated and identified which was found to be present in certain browned polypeptides such as bovine serum albumin and poly-L-lysine, and was assigned the structure 2-furoyl-4(5)-2(furanyl)-lH-imidazole. The compound was found to exist in a tautomeric state and has incorporated 1~

~ 4~

in its structure two peptide-derived amine nitrogens.
The incorporation of these amine nitrogens and two glucose residues in the compound suggested that its peptide-bound precursor may be implicated in the in viYo crosslinking of proteins by glucose, which is observed in the late stage of the Maillard process. [See Chang, J.C.F., Ulrich, P.C., Bucala, R., and Cerami, A. (1985) J. Biol. ChemVol. 260, pp. 7970-7974]. This chromophore made possible the identification of the advanced glycosylation end products and assisted additional investigations seeking to clarify the protein aging process and if possible, to identify the specific chemistry involved in an effort to develop methods and agents for its inhibition. It is to this purpose that the present application is directed.

SUMMARY OF THE INVENTION

In accordance with the present invention, a method and associated agents are disclosed for the inhibition of protein aging. In particular, agents for inhibiting protein aging due to the formation of advanced glycosylatlon end products may be selected from those materials capable of reacting with the early glycosylation product from the reaction of glucose with proteins and preventing further reactions. Thus, for example, compounds or compositions having active nitrogen-containing substituents such as hydrazine groups, have been theorized to be suitable, and compounds such as aminoguanidine, ~- hydrazinohistidine and lysine have been found to be suitable. These agents appear to react with the early glycosylation product at its reactive carbonyl and thereby prevent the same from later forming the advanced glycosylation end products which lead to protein crosslinks.

The present invention also relates to a method for inhibiting protein aging by contacting the initially 6 ~ ~$~

glycosylated protein at the stage of the early glycosylation product with a quantity of one or more of the agents of the present invention. In the instance where the present method has industrial application, one or more of the agents may be applied to the proteins in question, either by introduction into a mixture of the same in the instance of a protein extract, or by application or introduction into foodstuffs containing the protein or proteins, all to prevent premature aging and spoilage of the particular foodstuffs.

In the instance where the present method has therapeutic application, the animal host intended for treatment may have administered to it a quantity of one of more of the agents, in a suitable pharmaceutical form.
Administration may be accomplished by known techniques, such as oral, topical and parenteral techniques such as intradermal subcutaneous, intravenous or intraperitoneal injection, as well as by other conventional means.
Administration o~ the agents may take place over an extended period of time at a dosage level of, for example, up to about 25 mg/kg.

The ability to inhibit the formation of advanced glycosylation end products carries with it significant implications in all applications where protein aging is a serious detriment. Thus, in the area of food technology, the retardation of food spoilage would confer an obvious economic and social benefit by making certain foods of marginal stability less perishable and therefore more available for consumers. Spoilage would be reduced as would the expense of inspection, removal and replacement, and the extended availability of the foods could aid in stabilizing their price in the marketplace. Similarly, in other industrial applications where the perishability of proteins is a problems, the admixture of the agents of the present invention in compositions containing such proteins would facilitate the extended useful life of the `` 7 ~ 2~

same. Presently used food preservatives and discolordtion preventatives such as sulfur dioxide, known to cause toxicity including allergy and asthma in animals, might be replaced with compounds such as those described herein.

The present method has particular therapeutic application as the Maillard process acutely affects several of the significant protein masses in the body, among them collagen, elastin, lens proteins, and the kidney glomerular basement membranes. These proteins deteriorate both with age (hence the application of the term "protein aging") and as one of the sequelae of diabetes. Consequently, the ability to either retard or substantially inhibit the formation of advanced glycosylation end products carries the promise of favorably treating a significant adverse effect of diabetes and of course, improving the quality and perhaps duration of animal life.

Accordingly, it is a principal object of the present invention to provide a method for inhibiting the extensive cross-linking of proteins that occurs as an ultimate consequence of the reaction of the proteins with glucose, by correspondingly inhibiting the formation of advanced glycosylation end products.

It is a further object of the present invention to provide a method as aforesaid which is characterized by a reaction with an initially g!ycosylated protein identified as early glycosylation products.

It is a further object of the present invention to provide a method as aforesaid which prevents the rearrangement and cross-linking of the said early glycoslyation products to form the said advanced glycosylation end products.

It is a yet further object of the present invention to provide agents capable of participating in the reaction with the said early glycosylation products in the method as aforesaid.

It is a still further object of the present invention to provide therapeutic methods for treating the adverse consequences of protein aging, manifest in the embrittlement of animal protein and the browning and spoilage of foodstuffs.

Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing description which proceeds with reference to the following illustrative drawings.

BRIEF DESCRIPTION OF THE DRAWINGS
-FIGURE 1 is a graph showing the results of studies aimed at inhibiting the formation of advanced glycosylation end products in albumin which had been reacted with a quantity of glucose, on an in vitro basis.

FIGURE 2 is a graph showing the results of studies aimed at inhibiting protein entrapment and accumulation by glycosylated structural proteins such as collagen.

FIGURE 3A is a yraph of the degree of solubilization of collagen incubated with glucose~ with and without treatment with an agent of the present invention.

FIGURE 3B is a photograph of a polyacrylamide gel showing separation of protein fragments after cyanogen bromide digestion of collagen incubated with glucose with and without an agent of the present invention.

FIGURE 4 is a graph of the results of an in vivo study examining the extent of protein bound to the glomerular 9 ~Z~2~3 basement membrane of diabetic rats to certain of which an agent of the present invention had been administered.

DETAILED DESCRIPTION OF THE PREFERRE~ EMBODIMENT

In accordance with the present invention, a composition and associated methods have been developed which are believed to inhibit the formation of advanced glycosylation end products in a number of target proteins existing in both animals and plant material. In particular9 the invention relates to a composition which may contain one or more agents that are capable of inhibiting the formation of advanced glycosylation end products on such target proteins, by reacting with the carbonyl moiety of the early glycosylation product that is formed by the initial glycosylation of the protein.

It is the carbonyl group located near the junction between the sugar and protein segments of the early glycosylation product that is theorized to comprise an active site that causes the further cross-linking of the protein to form the advanced glycosylation end product, and likewise contributes to the entrapment of other proteins that is evident in the deve10pment in vivo of conditions such as skin wrinkling, certain kidney diseases, atherosclerosis, osteoarthritis and the like.
Similarly, plant material that undergoes nonenzymatic browning deteriorates and in the case of foodstuffs, becomes spoiled and inedible. Thus, the reaction with this carbonyl moiety is believed to inhibit the late stage Maillard effect.

The rationale of the invention is to use agents which block the post-glycosylation step, i.e., the formation of fluorescent chromophores such as that identified in Pongor, etal., supra. whose presence is associated with, and leads to, the adverse sequelae of diabetes and aging.
An ideal agent would prevent the formation of the chromophore and its associated cross-links of proteins to proteins and trapping of proteins on the other proteins, such as occurs in arteries and in the kidney.

The present invention does not attempt to prevent initial protein glycosylation, as it would be nearly impossible to use agents which prevent the reaction of gl~cose with protein amino groups. The agents that are capable of preventing initial glycosylation are likely to be highly toxic, and since the initial glycosylation comes to equilibrium in about three weeks, there is inadequate time available to achieve this objective. Instead, the ideal agent would prevent or inhibit the long-term, post-glycosylation steps that lead to the formation of the ultimate advanced glycosylation end product which are a direct cause of the pathology associated with aging and diabetes.

The chemical nature of the early glycosylation pro-ducts with which the compounds of the present invention is believed to react are speculative. Early glycosylation products with carbonyl moieties which are involved in the formation of advanced glyco-- ~%~
-lOa-sylation products, and which may be blocked by reaction with the compounds of the present invention, have been postulated. In one case the reactive carbonyl moieties of Amadori products or their further dehydration and/or rearrangement products, may con-dense to form advanced glycosylation endproducts.
Another proposed mechanism is the ~orm of reactive carbonyl compounds, containing one or more carbonyl moieties (such as glycoaldehyde or 3-deoxyglucosone) from the cleavage of Amadori or other early glyco-sylation products (see, for example, Gottschalk, A.
(1972) in The Glycoproteins (Gottschalk, A., ed) Part A, pp. 141-157, Elsevier Publishin~ Co., New York;
Reynolds, T.M. (1965) Adv. Food Res., 14, pp. 167-283), and by subsequent reactions with an amine or Amadori product to form carbonyl containing advanced glycosylation products.

Several investigators have studied the mechanism of advanced glycosylation product formation. In vitro studied by Eble et al., (1983), "Nonenzymatic Gluco-sylation and Glucose-dependent Cross-linking of Protein", J. BIOL CHEM. 258:9406-9412, concerned the crosslinking of glycosylated protein with nonglyco-sylated protein in the absence of glucose. Able et al -lOb-sought to elucidate the mechanism of the Maillard reaction and accordingly conducted controlled initial glycosylation of RNAase as a model system, which was then examined under varying conditions.

Accordingly, the compositions useful in the present invention comprise or contain agents capable of reactlng with the active carbonyl intermediate of the early glycosylation product. Suitable agents include compounds having an active nitrogen-containing group or substituent such as a hydrazine group. Also, the agent or compound may be at least partially derived from an amino acid, including the esters and amides thereof, as compounds having this derivation are generally biocompatible with the target proteins to be contacted. For example, the agent may comprise a compound selected from the group consisting of am:ino-guanidine, c~-hydrazinohistidine and lysine, and possibly mixtures of these agents or compunds. Each of these agents or compounds possesses an active nitrogen-containing substituent that is believed to react with the carbonyl of the early glycosylation product. Consequently, reaction of the agents with the glycosyl-lysine miety of a proteln would prevent this moiety from forming crosslinks with other groups.

Hollis and Striskberger (Diabetologia 28:282-5 [1985]) found that in vivo administration of the compound ~-hydrazinohydrazine, a known inhibitor of the enzyme histidine decarboxylase, reduces the accumulation of albumin in the aortas of rats. The authors proposed that the drug acted to reduce production of histamine in this tissue, and that histamine is ~herefore the mediator of low density lipoprotein accumulation which is implicated in atherosclerotic disease. The findings of ~ollis and Strickberger are distinguishable from the concept and application of the present invention on several grounds.
A primary distinction is that the authors were concerned with protein accumulation that is observed in diabetic animals, and not advanced non-enzymatic glycosylation of proteins. Moreover, the mechanism of histamine synthesis supression by ~-hydrazinohistidine suggested by the authors, is functionally dist;nct from the underlying concept of the present invention, and it is believed, may even be placed in question by the latter.

Thus, the agents of the present invention have been identified and tested on the basis of their ability to react with the carbonyl moiety of the early glycosylation product, and would not have been suggested from the work of Hollis and Strickberger. In particular, aminoguanidine is known to increase levels of histamine (See Lindberg, S., Tornqvist, A., "The Inhibitory Effect of Aminoguanidine on Histamine Catabolism in Human Pregnancy", ACTA OBSTET. GYNECOL. SCAND., 45: 131-139, 1956), and ~-~ydrazinohistidine and aminoguanidine therefore have opposing effects on histamine levels. It can therefore be seen that the present findings that both ~-hydrazinohistidine and aminoguanidine have efficacy in vivo and in vitro to reduce protein crosslinking rules out from consideration and consequently distinguishes the mechanism proposed by Hollis and Strickberger as the ~ 12 21~

explanation of the manner in which these drugs might work to reduce advanced glycosylation end product formation.

The compound aminoguanidine is known to have low toxicity in animals. According to the 1978 Registry of Toxic Effects of Chemical Substances~ aminoguanidine base has a LD50 when administered subcutaneously of 1258 mg/kg in rats and 963 mg/kg in mice. The hydrochloride derivative had a LD50 in rats of 2984 mg/kg when given subcutaneously. The latter compound exhibits very low lo ~oxicity.

In the instance where the composition of the present invention is utilized for in vivo or therapeutic purposes, it may be noted that the compounds or agents used therein are biocompatible. Pharmaceutical compositions may be prepared with a pharmaceutically effective quantity of the agents or compounds of the present invent;on and may include a pharmaceutically acceptable carrier, selected from known materials utilized for this purpose. Such compositions may be prepared in a variety of forms, depending on the method o~ administration. For example, aminoguanidine may be derivatized to the hydrochloride salt from the commercially available bicarbonate salt to improve its solubility and to make it less irritating for intraperitoneal injection. Also, a liquid form would be utilized in the instance where administration is by intravenous or intraperitoneal injection, while, if appropriate, tablets, capsules, etc., may be prepared for oral administration. For application to the skin a lotion or ointment may be formulated with the agent in a suitable vehicle, perhaps including a carrier to aid in penetration into the skin. Other suitable forms for administration to other body tissues are contemplated.

The present invention likewise relates to methods for inhibiting the formation of advanced glycosylation end ~ 13 ~.%94~
products, which comprise contacting the target proteins with the composition of the present invention. In the instance where the target proteins are contained in foodstuffs, whether plant or animal origin, these foodstuffs could have applied to them by various conventional means a composition containing the present agents. Likewise, in ~he instance where therapeutic applications are intended, the animals to be treated would have administered to them a regular quantity of the pharmaceutical composition of the present i~vention.
Administration could take place for example daily, and an effective quantity of the agent or compound of the present invention could range up to 25 mg/kg of body weight of the animal. A topical preparation may, for example, include up to 10% of the agent or composition in an ointment or lotion for application to the skin.
Naturally, some variation in these amounts is possible, and the suggested amounts are provided ;n fulfillment of applicants' duty to disclose the best mode for the practice of the present invention.

As is apparent from a discussion of the environment of the present invention, the present methods and compositions hold the promise for arresting the aging of key proteins both in animals and plants, and concomitantly, conferring both economic and medical benefits as a result thereof. In the instance of foodstuffs~ the administration of the present composition holds the promise for retarding food spoilage thereby making foodstuffs of increased self life and greater availability to consumers~. Replacement of currently-used preservatives, such as sulfur dioxid\e known to cause allergies and asthma in humans, with non-toxic, biocompatible compounds is a further advantage of the present invention.

The therapeutic implications of the present invention relate to the arrest of the aging process which has as ,.

indicated earlier, been identified in the aging key proteins by advanced glycosylation and cross-linking.
Thus, body proteins such as collagen, elastin, lens proteins, nerve proteins and kidney glomerular base-ment membranes would all benefit in their longevity and operation from the practice of the present invention. It is further theorized that the present invention would reduce the incidence of pathologies involving the entrapment of proteins by cross-linked target proteins including retinopathy, cataracts, diabet.ic kidney disease, glomerulosclerosis, peri-pheral vascular disease, arteriosclerosis obliterans, peripheral neuropathy, hypertension, atherosclerosis, osteoarthritis, periarticular rigidity, loss of elasticity and wrinkling of skin, stiffening of joints, glomerulonephritis, etc. Likewise, all of these conditions are in evidence in patients afflicted with diabetes mellitus. Thus, the present therapeutic method is relevant to treatment of the noted con-ditions in patients either of advanced age or those suffering from one of the mentioned pathologies.

, "

~2~Z18 -14a-The present invention will be better understood from a consideration of the following illustrative examples, reviewing the selection and testing of certain of the agents of the present invention on both an in vitro and in vivo basis.

To measure the ability of certain of the agents of the present invention to inhibit the production of advanced glycosylated end products in vitro, albumin and glucose were incubated together for two weeks in the presence of several test agents. Samples were taken at regular intervals for analysis. Advanced glycosylation endproducts were measured as appearance of fluorescent compounds, and eal-ly glycosylation products were measured by incorporation of radio-labeled glucose into albumin.

." ~, Reaction conditions were as follows. Each mixture contained 6 mg/mL bovine serum albumin, 200 mM glucose, 200 mM test agent (either aminoguanidine hydrochloride, ~ hydra~ino-histidine, or lysine), and approximately 9.5 x 106 counts per minute of 14C-glucose ln 0.5~ phosphate buffer, pH 7.6.
The radiolabeled glucose was prepurified before use to eliminate breakdown products which might react with the albumin and lead to an erroneous indication of the degree of early glycosylation product formation. Reaction mixtures were incubated at 37C and samples were taken after 0.5, 1.0, 1.5, and 2 weeks. Control mixtures lacked glucose or agent.

After the incubation periods, samples were treated as foll.ows. After dialysis to remove all unbound glucose, the amount of protein present was measured with a standard dye-bindiny assay. The amoun-t of glucose which became bound to the albumin, a measure of early glycosylation products, was determined by precipitating albumin with trichloroacetic acid and measuring the radioactivity o the bound glucose using scintillation counting. ~dvanced glycosylation end products were quantitated by de-termining the fluorescence of the albuminas described in the above-mentioned Canadian Patent 1,250,587, and as described by Pongor et al., Supra.
Spectral measurements on excitation and emission maxima were made on all samples to ensure that these values had not been shifted as a result of adduct formation with inhibitors.

The results of this experiment are expressed graphically in FIGURE 1. For each sample, incorporation of radiolabeled glucose is indica-ted by the solid portion of the bar, and fluorescence is indicated in the open portion of the bar.
All values are expressed as per milligram of albumin. In all further discussions, aminoguanidine refers to the hydrochloride derivative.

~ .

~;~9421~
The results show that glucose and albumin react to form a large amount of f uorescent advanced glycosylation endproducts after 0.5, 1, 1.5, and 2 weeks of incubation ("GLUCOSE + BSA"). Inclusion of 200 mM aminoguanidine dramatically reduced by as much as eight-fold the formation of fluorescent compounds, by comparison with the control samples after a two week incubation ("BSA ~
GLUCOSE + I#2). Inclusion of 200 mM ~-hydrazinohistidine also reduced formation of advanced glycosylation endproducts as measured by fluorescence ("BSA + GLUCOSE +
I#l). Lysine appeared to cause an increase in fluorescent compound formation ("BSA + GLUCOSE + LYS"), but as will be seen in the next experiment, it had the ability to reduce protein crosslinking. The amount of early glycosylation endproducts, as measured by glucose incorporation, was nearly unchanged in all reactions.
The control incubation without glucose showed little development of fluorescent products (A).

These results show that aminoguanidine, and to a lesser extent, ~-hydrazinohist;dine, reduce the formation of fluorescent compounds when glucose and albumin react over time, and indicate that these two agents reduce the amount of advanced glycosylation endproducts which form The agents do not alter the formation of early glycosylation products.

EXAMPLE II

To more precisely measure the effect of the agents on the inhibition of protein crosslinking, an assay system was devised to measure the extent of in vitro binding of a soluble protein to an insoluble protein. This assay system mimicks the events which occur in tissues in w~ich serum proteins become bound to proteins in extravascular matrix and which lead to accumulation of protein and narrowing of vessel lumina in several other tissues.
These events in vivo give rise to kidney disease and ~ 17 21~3 atherosclerotis disease, and lead to the pathologies associated with diabetes and aging.

To measure protein trapping (i.e., binding or accumulation), gelatin (collagen) was coupled to activated agarose beads (Affigel 10, ~io-Rad Laboratories) by routine methods. After coupling, all remaining active sites on the beads were quenched by reaction with glycine ethyl ester.

The beads were incubated for two weeks with bovine serum albumin and 400 mM glucose-6-phosphate, a more reactive form of glucose which forms early glycosylation products with proteins ~ore rapidly than does glucose. Also included in some experiments were the test a~ents, aminoguanidine, ~ -hydrazinohistidine, or lysine, at a concentration of 200 mM. The bovine serum albumin was radioiodinated so that the amount which became bound to the beads could be measured. The amount oF radiolabel that became bound to the beads in a direct measure of protein trapping.

After a two-week incubation of the reaction mixtures at 37~C, the beads were washed extensively with chaotropic agents and the covalently bound radioactivity was determined. The results are set forth in FIGURE 2.

The left bar shows the control level of radiolabel ~5 incorporated into the beads in the absence o~
glucose-6-phosphate and in the absence of any test agents ("CONTROL COLLAGEN"). The second bar shows the high amount of incorporation in the presence of glucose-6-phosphate ("NEG. COLLAGEN"). This is likened to the presence of high concentrations of glucose in the blood of uncontrolled patients with diabetes and the patholo3ical sequelae ~hich result.

~a~ ~hAr~

"~
21 ~

The figure shows that the amount of protein trapping in the presence of either aminoguanidine ("NEG. COLLAGEN +
I#2") or ~-hydrazinohistidine ("NEG. COLLAGEN + I#l'~ is greatly reduced. Lysine alse reduced the amount of protein trapping to an e~tent similar to that of aminoguanidine (not shown). The results show the potential value of these compounds in vivo for reducing the trapping or soluble protein on to membranes and other tissues9 and further evidence that these agents may be of value in reducing the pathogenesis of diabetes and aging.

EXAMPLE III

As a further evaluation of the compound aminoguanidine as a model for the prevention of protein trapping, crosslinking and formation of advanced glycosylation endproducts, the following experiment using calf skin collagen was performed. Collagen is a protein in the skin responsible for the suppleness of skin, and crosslinking leads to wrinkling, decreased elasticity, reduced susceptibility to proteolytic degradation, and other changes.

Collagen from samples of calf skin were extracted into acetic acid and then precipitated with 0.6 M sodium chloride. These procedures removed from the solution skin collagen that was already permanently crosslinked or denatured. Native collagen fibrils were reformed by dialysis against 0.02M phophate buffer and these were incubated for 3 weeks at 35C in the presence of 140 mM
glucose and with or without 200 mM aminoguanidlne. After incubation, the samples were dialyzed and the degree of crosslinking was determined by two methods. Flrst, the amount of reacted collagen which could be solubilized by treatment in 2% sodium dodecyl sulfate at 100C was measured.

19 ~L2~

As shown in FIGURE 3A, collagen incubated with glucose and aminoguanidine was as soluble as collagen incubated in buffer alone. In contrast, collagen incubated in glucose without aminoguanidine was only 50% as soluble.
This is further evidence that aminoguanidine may have utility in the prevention of age-related changes in skin and other tissues.

The reacted collagen was further examined by cleaving it into fragments using cyanogen bromide treatment in formic acid. The resulting protein fragments were separated by size by sodium dodecyl sulfate - polyacrylamide gel electrophoresis. After electrophoresis, the protein fragments were identified in the gel using silver staining. The gel is shown in FIGURE 3B.

Lane B contains collagen that was incubated with glucose alone. It is noted that a large amount of high molecular weight fragments form d continuous band at the top of the yel, indicating a large range of high molecular weight fragments. Some of this material could not enter the gel and is present in the 30~ stacking gel above the gradient gel. Lane C contains the collagen incubated with glucose and aminoguanidine, and it is noted that there is no large amount of high molecular weight material at the top of the lane~ as all of the protein fragments separate well in the lower part of the gel. Lane A shows collagen incubated in PBS alone. The far left lane is a series of molecular weight markers~ Identical results were observed with and without the presence of disulfide bond reducing agents in the electrophoresis buffer.

The above data indicate that~aminoguanidine reduces the amount of crosslinking which occurs when collagen is incubated with glucose, and suggest the utility of this agent for topical application to skin to prevent -~ 20 ~ 21 ~

age-related changes, including loss of elasticity and wrinkling.

The above in vitro experiments all point to the value of aminoguanidirle as an agent to inhibit the formation of advanced glycosylation endproducts which form in vitro from proteins incubated in the presence of glucose. As glucose is present in the body and is elevated in amount in diabetes, and as proteins in the body are known to undergo crosslin~ing and form fluorescent compounds all indicative of advanced glycosylation endproducts, use of this agent in vivo might be useful in the prevention of the pathology associated with diabetes and changes that occur during aging.

Accordingly, the following experiment was performed to test the hypothesis of the present invention in an in vivo environment~
EXAMPLE IV

To measure the level of advanced glycosylation endproducts in vivo, the kidneys of rats were examined for serum proteins which became attached to glomerular basement membranes. This was determined to be a good model in which to study this process as it is known that significant kidney pathology occurs in untreated diabetes as a result of the build-up of extravasated plasma protein in the extravascular matrix in this organ.

The experiment consisted of giving both normal and diabetic rats daily intraperîteoneal doses of the agent aminoguanidine hydrochloride at a dose of 25 mg per kilogram of body weight, for a period of 16 weeks. The hydrochloride salt of aminoguanidine was used as it is more soluble and less irritating tha~ the parent free base compound. Diabetes was induced prior to drug therapy with a single dose of streptozotocin. Control animals, both diabetic and normal, received no drug.

lZ~

At the end of the agent therapy, animals were sacrificed and the kidneys were removed. Each organ was removed from its capsule and the medulla was removed. The remainder of the tissue, principally containing glomeruli, was frozen on dry ice and stored at -70C.
Tissue from 5 animals in each treatment group was combined for processing.

To prepare glomerular basement membranes, tissue was cut into slices and passed through a series of sieves (170, 100 and 270) to separate glomeruli from tubules and other undesired tissue elements as described (Beisswenger, P.J., Spiro, R.G., DIABETES, 22:180-193, I973.).
Glomerular purity was found to be 80-90%. The final material was collected and centrifuged at 1500 rpm for fifteen minutes to pellet the glomeruli, which were frozen at -70C.

Thawed isolated glomeruli were then disrupted by treatment in a Branson Sonifier 200 cell disrupter for four one-minute intervals on ice with a one-minute rest between sonications. Samples were examined in a phase contrast microscope to ensure that all of the glomeruli were disrupted. Glomerular basement membranes were then pelleted by centrifugation at 3000 rpm for ten minutes, washed with 1 M sodium chloride followed by distilled water. The remaining pellet of purified glomerular basement membranes was frozen and lyophil;zed.

An enzyme immunoassay was used to measure the amount of serum immunoglobulin G (IgG) that became bound to the glomerular basement membranes of the normal and diabetic animals after treatment with and without the agent. To measure IgG, 6 mg samples o~ lyophilized glomerular basement membrane tissue was suspended in 0.5 mM of 0.05 M carbonate buffer, pH 7.6, and 0.5 mM of a 1:5,000 dilution of rat anti-IgG antibody conjugated to alkaline ~ 2~ ~

phosphatase (Dynatech Corp.) was added. The mixture was incubated overnight in polystyrene tubes which were preblocked by incubation for two hours in 3% goat serum plus 0.05% Tween 20 in phosphate buffered saline (PBS), followed by two rinses in PBS plus Tween.

After overnight incubation to allow the antibody to bind to any IgG crosslinked to the glomerular basement membranes, the membranes were pelleted by centrifugation at 3200 rpm for five minutes and were washed ~ree of the unbound antibody-enzyme conjugate with four rinses with PBS plus Tween followed by three rinses with distilled water. To measure the amount of antibody-enzyme conjugate remaining bound, 0.5 mM of substrate solution (containing 1 mg/mL para-nitrophenylphosphate in 10%
diethanolamine, pH 9.8~, was added and incubations were carried out for thirty minutes at room temperature. The react;on was stopped with the addition of 0.2 mL of M
sodium hydroxide, and the absorbance at 400 nm was measured.

Z0 FIGURE 4 shows the results of this experiment. As can be seen, diabetic animals had a high level of IgG bound to their glomerular basement membranes ("D")9 and normal animals had about one-fifth the amount ("N"). Diabetic animals which received daily doses of aminoguanidine hydrochloride showed the same low level of IgG in normal animals ("D ~ I"). Normal animals receiving the drug had about the same low level ("N + I").

These experiments indicated that aminoguanidine prevented the trapping and accumulation of this plasma protein on the rat glomerular basement membranes. Presumably the trapping of this and other serum proteins in the kidney, eye, on artery walls, and in other tissues known to be affected from this pathology would likewise be reduced.
Trapping of lipoproteins on artery walls is known to contribute to atherosclerotic disease.
~ ~de ~ rK

il ;~99~21~3 These in vivo experiments provide further evidence from the in vitro experiments that this type of drug therapy has benefit in reducing the pathology associated with the advanced glycosylation of proteins and the formation of crosslinks between proteins and other macromolecules.
Drug therapy may be used to prevent the increased trapping and crosslinking of proteins that occurs in diabetes and aging which leads to sequelae such as arterial disease, including renal disease, hypertension, retinal damage, and ex~ra-vascularly, damage to tendons, ligaments~ and other joints. This therapy might retard atherosclerosis and connective tissue changes that occur with diabetes and aging. Both topical, oral, and parenteral routes of administration to provide therapy locally and systemically are contemplated.

This invention may be emobodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

Claims

1. A composition for inhibiting the advanced glycosylation of a target protein comprising an agent capable of reacting with a carbonyl moiety of an early glycosylation product resulting from the initial glycosylation of the target protein, together with a carrier therefor, said agent being present in an amount effective to inhibit the advanced glycosylation of the target protein.

2. A composition of claim 1, wherein said agent comprises a compound having an active nitrogen-containing substituent.

3. A composition of claim 2, wherein said active nitrogen-containing substituent is a hydrazine group.

4. The composition of claim 2, wherein said compound is at least partially derived from a material selected from the group consisting of amino acids, their esters and amides and mixtures.

5. The agent of claim 2, wherein said compound is selected from the group consisting of amino-guanidine,?-hydrazinohistidine and mixtures thereof.

6. A composition of claim 2, wherein said compound is lysine.

7. A composition of claim 2, wherein said compound is selected from the group consisting of aminoguanidine, ?-hydrazinohistidine, lysine and mixtures thereof.

8. The composition of claim 5, wherein said compound is selected from the group consisting of aminoguanidine hydrochloride, aminoguanidine bicar-bonate and mixtures thereof.

9. The composition of claim 1, wherein said composition and said agent are useful for the treat-ment of the complications of diabetes and aging caused by the accumulation of advanced glycosylation end-products in mammals.

10. A pharmaceutical composition for administration to an animal to inhibit the advanced glycosylation of a target protein within said animal, comprising a pharmaceutically effective amount of an agent capable of reacting with a carbonyl moiety of an early glycosylation product resulting from the initial glycosylation of said target protein, and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, wherein said agent comprises a compound having an active nitrogen-containing substituent.

12. The pharmaceutical composition of claim 11, wherein said active nitrogen-containing substituent is a hydrazine group.

13. The pharmaceutical composition of claim 11, wherein said compound is at least partially derived from a material selected from the group consisting of amino acids, their esters and amides and mixtures.

14. The pharmaceutical composition of claim 11, wherein said compound is selected from the group consisting of aminoguanidine, ?-hydrazinohistidine and mixtures thereof.

15. The pharmaceutical composition of claim 11, wherein said compound is lysine.

16. The pharamaceutical composition of claim 11, wherein said compound is selected from the group consisting of aminoguanidine, ?-hydrazinohistidine, lysine and mixtures thereof.

17. The pharmaceutical composition of claim 14, wherein said aminoguanidine is selected from the group consisting of aminoguanidine hydrochloride, amino-guanidine bicarbonate and mixtures thereof.

18. The pharmaceutical composition of claim 10, wherein said composition and said agent are useful for the treatment of the complications of diabetes and aging caused by the accumulation of advanced glyco-sylation endproducts in mammals.

19. Use of an agent capable of reacting with a carbonyl moiety of an early glycosylation product resulting from the initial glycosylation of a target protein, for inhibiting the advanced glycosylation of the target protein.

20. The use of claim 19, wherein said agent comprises a compound having an active nitrogen-containing substituent.

21. The use of claim 20, wherein said active nitrogen-containing substituent is a hydrazine group.

22. The use of claim 13, wherein said compound is at least partially derived from a material selected from the group consisting of amino acids, their esters and amides and mixtures.

23. The use of claim 19, wherein said compound is selected from the group consisting of amino-guanidine, ?-hydrazinohistidine and mixtures thereof.

24. The use of claim 19, wherein said compound is lysine.

25. The use of claim 19, wherein said compound is selected from the group consisting of amino-guanidine, ?-hydrazinohistidine, lysine, and mixtures thereof.

26. The use of claim 23, wherein said amino-guanidine is selected from the group consisting of aminoguanidine hydrochloride, aminoguanidine bicar-bonate and mixtures thereof.

27. The use of claim 19, wherein said target protein is found in foodstuffs.

28. Use of an agent capable of reacting with a carbonyl moiety of an early glycosylation product resulting from the initial glycosylation of a target protein, for inhibiting the formation of advanced glycosylation end products of the target protein within an animal.

29. Use of claim 28, wherein said target protein is selected from the group consisting of collagen, elastin, lens protein, blood vessel walls, nerve protein and glomerular basement membrane.

30. The use of claim 29, wherein said agent comprises a compound having an active nitrogen-containing substituent.

31. The use of claim 30, wherein said active nitrogen-containing substituent is a hydrazine group.

32. The use of claim 30, wherein said compound is at least partially derived from a material selected from the group consisting of amino acids, their esters and amides and mixtures.

33. The use of claim 30, wherein said compound is selected from the group consisting of amino-guanidine, ?-hydrazinohistidine and mixtures thereof.

34. The use of claim 33, wherein said amino-guanidine is selected from the group consisting of aminoguanidine hydrochloride, aminoguanidine bicar-bonate and mixtures thereof.

35. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of the complications of diabetes and aging caused by accumulation of advanced glycosylation endproducts in the body.

36. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of diabetic kidney disease.

37. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of glomerulosclerosis.

38. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of peripheral vascular disease.

39. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of atheroscloerosis.

40. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of arteriosclerosis obliterans.

41. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of peripheral neuropathy.

42. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of retinopathy.

43. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of cataracts.

44. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of hypertension.

45. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of periarticular rigidity.

46. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of osteoarthritis.

47. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of loss of elasticity and wrinkling of skin.

48. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of stiffening of joints.

49. The use of claim 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33 or 34, adapted for the treatment of glomerulonephritis.

50. A pharmaceutical composition of claim 10, 11, 12, 13, 14, lS, 16 or 17, for use in the treatment of diabetes and aging caused by accumulation of advanced glycosylation endproducts in the body.

51. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of diabetic kidney disease.

52. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of glomerulosclerosis.

53. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of peripheral vascular diseases.

54. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of atherosclerosis.

55. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of arterosclerosis obliterans.

56. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of peripheral neuropathy.

57. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of retinopathy.

58. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of cataracts.

59. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of hypertension.

60. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of periarticular rigidity.

61. A pharmacetucial composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of osteoarthritis.

62. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of loss of elasticity and wrinkling of skin.

63. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of stiffening of joints.

64. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of glomerulonephritis.

65. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, for use in the treatment of parenteral administration.

66. A pharmaceutical composition o claim 10, 11, 12, 13, 14, 15, 16 or 17, in a form for topical administration.

67. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, in the form of an ointment containing said agent in an amount of up to about 10% by weight.

68. A pharmaceutical composition of claim 10, 11, 12, 13, 14, 15, 16 or 17, in a form for oral administration.

69. A composition of claim 50, in a form for parenteral administration.

70. A composition of claim 50, in a form for topical administration.

71. A composition of claim 50, in the form of an ointment containing said agent in an amount of up to about 10% by weight.

72. A composition o claim 50, in a form or oral administration.

#41-08/19/1991 3 ~